Trifarotene
Based on 1 Customer Validation
Trifarotene (CD5789) is a potent and selective RARγ agonist. Trifarotene (CD5789) shows ～65-fold and ～16-fold selectivitiy for the RARγ (EC50=7.7 nM) over RARα (EC50=500 nM) and RARβ (EC50=125 nM), respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.12%
- No. CAS: 895542-09-3
- Fòrmula: C29H33NO4
- Peso molecular:459.58
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-14652
TamibaroteneApoptosis Inducer -
HY-15388
TazaroteneRAR Agonist -
HY-10475
AM580RARα Agonist -
HY-15682
TTNPBApoptosis Inducer -
HY-107765
LY2955303RARγ Antagonist -
HY-100532
CD437RARγ Agonist -
HY-16684
AGN-195183RARα Agonist -
HY-14649
Retinoic acidRAR Agonist -
HY-15373
FenretinideAutophagy Inducer -
HY-14799
PalovaroteneRARγ Agonist -
HY-15127
IsotretinoinAnti-acne Agent -
HY-B0091
AdapaleneRAR Agonist
Actividad biológica
Descripciòn
In Vitro
Trifarotene (CD5789) (3.3 μL 0.33 cm2 ; 24 hours) involves in keratinization, desquamation, cornification and cell adhesion in reconstructed human epidermis (RHE). The mean EC50 on the combined target genes is 0.0048% for Trifarotene[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rhino mice [2]
-
Dosage:0.001%, 0.0025%, 0.005% and 0.01% in a cream at 25 mg/mouse (5 cm2 surface on the back skin on a 5 mg/cm2 basis)
-
Administration:Topical application; once a day; 11 days
-
Result:Increased the epidermis thickness by 275% (66 μm) and the transepidermal water loss (TEWL) by 285% (26 g/h/m2 ).
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 895542-09-3
-
Appearance Solid
-
Peso molecular 459.58
-
Fòrmula C29H33NO4
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(C2=CC=C(OCCO)C(C3=CC=C(N4CCCC4)C(C(C)(C)C)=C3)=C2)C=C1)O
-
Synonyms
CD5789
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvente y solubilidad
In Vitro:
DMSO : 250 mg/mL (543.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Etienne Thoreau, et al. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1736-1741. [Content Brief]
[2]. J Aubert, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene. Br J Dermatol. 2018 Aug;179(2):442-456. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1759 mL | 10.8795 mL | 21.7590 mL | 54.3975 mL |
| 5 mM | 0.4352 mL | 2.1759 mL | 4.3518 mL | 10.8795 mL | |
| 10 mM | 0.2176 mL | 1.0879 mL | 2.1759 mL | 5.4397 mL | |
| 15 mM | 0.1451 mL | 0.7253 mL | 1.4506 mL | 3.6265 mL | |
| 20 mM | 0.1088 mL | 0.5440 mL | 1.0879 mL | 2.7199 mL | |
| 25 mM | 0.0870 mL | 0.4352 mL | 0.8704 mL | 2.1759 mL | |
| 30 mM | 0.0725 mL | 0.3626 mL | 0.7253 mL | 1.8132 mL | |
| 40 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3599 mL | |
| 50 mM | 0.0435 mL | 0.2176 mL | 0.4352 mL | 1.0879 mL | |
| 60 mM | 0.0363 mL | 0.1813 mL | 0.3626 mL | 0.9066 mL | |
| 80 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6800 mL | |
| 100 mM | 0.0218 mL | 0.1088 mL | 0.2176 mL | 0.5440 mL |
Trifarotene Related Classifications
HY-100256 Related Classifications
Powered by Bioz